According to many questions arising in clinical laboratories community on quality assessment and performance of In Vitro Diagnosis (IVDs) process in Iran, we are publishing a descriptive detailed process of Ministry of Health & Medical Education (MHME) role in achieving a permit for importing or local production of IVDs, supervisions on distribution, consumption, post marketing monitoring, limitations, and future prospects of Reference Health Laboratory (RHL) and its role in improving each step. The quality assessment & performance of IVDs program, is among other important quality assurance issues in medical laboratories of Iran started at RHL of MHME many years ago. At that time the results of a data set produced by RHL was the base for introducing and choosing of a product in the market. However, in recent years, issues such as introducing different technologies, competition of companies (local manufactures /importers), variety in clinical assessment analysis along with significant technical performance differences among IVDs in conducted analytical and clinical studies, and also different relevant certificates and approvals in a product technical file, have caused the clinical laboratories & technology management office to breakdown the evaluation process and consider other effective parameters to improve the investigation steps. These processes which at present are being proceeded in Medical Equipment office (MEO) with RHL cooperation for reviewing the technical file and performance evaluation are as follows (1- 
The responsibility of RHL, as mentioned earlier, is reviewing the technical file of products in details by its expert technologist, and performance evaluation in cases that is needed. If the gathered data are complete and adequate, they are presented at "Registry Committee" and the final result is then reported to MEO. The members of IVDs Registry Committee, held 2-3x monthly at RHL, are RHL general director and representatives from two offices as fixed members. In addition, experts from other related organs may be invited to attend the relevant sessions of the committee. The final decision of committee is categorized in four different groups:
 To evaluate a product technically at RHL or other collaborating laboratories based on RHL protocol.  To receive an import permit for a limited number of products after necessary quality and IVDs performance evaluation in collaborating laboratories at specific time period determined by RHL.  To confirm and register without initial technical evaluation process. Products from distinct companies/manufactures having national /international valid certificates, long satisfactory marketing history are considered in this group. Their evaluation is through post marketing surveillance (PMS).
 To return unacceptable product files to requesting company by MEO.
3-Post Marketing Monitoring of IVDs
Medical device manufactures and distributers should ensure that the products comply with certain requirements and regulations and do not endanger health or safety in a community once they are on the market (2,3). These requirements include such things as established and defined tracking system, reporting of device malfunctions, serious injuries, post market surveillance studies, post approval studies in order to improve calibration-upgrading-traceability-product development protocol services including installationtraining, maintenance-and product recall. One of the problems influencing the quality of clinical laboratory data randomly in Iran is related to devices that are already available in the market and they tend to fail customer or user expectation for quality or to meet performance specifications. In such cases they are subjected to" Complaint Reporting" to responsible organs and health care professionals. Any indication of complaint (oral, written,…) may be submitted to MEO and RHL, handled effectively, thoroughly analyzed and the manufactures or distributers be informed of the result/s. Then necessary corrective or preventative actions shall be taken that are of help to reduce the quality risks involved in IVDs quality and performance. Efficiency and quality of this system depend on many factors such as professional commitment, technical management expertise, and technical personnel as if carelessness in finding and reporting quality based deficiencies of a product may rise and lead to health safety problems. In addition, it may cause an unnecessary assessment procedure to begin.
The Challenges & Future Prospects of RHL
In fact what has been achieved so far at clinical laboratories & technology management of MHME with MEO and RHL collaborating and help of other organs like CDC, Pasteur institute of Iran, is strengthening the process of quality control activities that have been started many years
